

**Patient:**  
 DOB:                      Age:                      Gender:  
**Patient Identifiers:**  
  
**Visit Number (FIN):**

**Client:**  
  
**Physician:**

ARUP Test Code: 2009288  
  
 Collection Date: 08/23/2019  
 Received in lab: 08/25/2019  
 Completion Date: 08/27/2019

## Interpretive Summary

Consistent

All results are CONSISTENT with supplied medications.

## Interpretive Consultation

**DRUGS EXPECTED:**  
 FENTANYL

CONSISTENT with medications provided:  
 FENTANYL: based on fentanyl, norfentanyl

Interpretation depends on accuracy and completeness of patient medication information submitted by client.

Patient Results - Current *		Patient Results - Historical Trend		
<b>Collection Date</b>	<b>8/23/2019</b>	<b>Collection Date</b>	<b>7/24/2019</b>	<b>6/26/2019</b>
Creatinine, Urine	27.1	Creatinine, Urine	137.7	45.4
Fentanyl (cutoff 2 ng/mL)	<b>Present</b>	Fentanyl (cutoff 2 ng/mL)	<b>Present</b>	<b>Present</b>
Norfentanyl (cutoff 2 ng/mL)	<b>Present</b>	Norfentanyl (cutoff 2 ng/mL)	<b>Present</b>	<b>Present</b>
ARUP Accession	19-235-131690	ARUP Accession	19-205-132290	19-177-107110

\* For details, see report on following page.

**NOTE:** Consecutive test results are displayed on this chart; however, this result set may be incomplete due to variations in the demographic information submitted for prior tests. If the information shown on this chart appears incomplete, please consult the patient's prior charts.



Patient:  
 ARUP Accession: 19-235-131690

# Pain Management Drug Screen with Interpretation by High-Resolution Time-of-Flight or Tandem Mass Spectrometry and Enzyme Immunoassay, Urine

Patient: | Date of Birth: | Gender: | Physician:  
Patient Identifiers: | Visit Number (FIN):

---

## Interpretive Comments

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration must be greater than or equal to the cutoff to be reported as present. If specific drug concentrations are required, contact the laboratory within two weeks of specimen collection to request quantification by a second analytical technique. Interpretive questions should be directed to the laboratory.

Results based on immunoassay detection that do not fit clinical expectations should be interpreted with caution. Confirmatory testing by mass spectrometry for immunoassay-based results is available at an additional fee within two weeks of specimen collection.

For medical purposes only; not valid for forensic use.

For further information, consult [aruplab.com/pain](http://aruplab.com/pain).

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: [aruplab.com/CS](http://aruplab.com/CS)



Patient:  
ARUP Accession: 19-235-131690

# Pain Management Drug Screen with Interpretation by High-Resolution Time-of-Flight or Tandem Mass Spectrometry and Enzyme Immunoassay, Urine

Patient: \_\_\_\_\_ | Date of Birth: \_\_\_\_\_ | Gender: \_\_\_\_\_ | Physician: \_\_\_\_\_  
 Patient Identifiers: \_\_\_\_\_ | Visit Number (FIN): \_\_\_\_\_

Drug Analyte	Result	Cutoff	Notes
<b>OPIOIDS, IMMUNOASSAY</b>			
Methadone	Not Detected	150 ng/mL	
Propoxyphene	Not Detected	300 ng/mL	
Tramadol	Not Detected	200 ng/mL	
<b>COCAINE, IMMUNOASSAY</b>			
Benzoylcegonine	Not Detected	150 ng/mL	cocaine metabolite
<b>BARBITURATES, IMMUNOASSAY</b>			
Barbiturates	Not Detected	200 ng/mL	detects amobarbital, butalbital, pentobarbital, phenobarbital, secobarbital, and others
<b>OTHERS (IMMUNOASSAY OR SPECTROPHOTOMETRY)</b>			
Ethyl glucuronide	Not Detected	500 ng/mL	ethanol metabolite
Marijuana metabolite	Not Detected	20 ng/mL	9-carboxy-tetrahydrocannabinol; does not distinguish between prescribed and illicit forms
PCP	Not Detected	25 ng/mL	phencyclidine
Carisoprodol	Not Detected	100 ng/mL	detects carisoprodol and meprobamate
<b>OPIATES, MASS SPEC</b>			
Codeine	Not Detected	40 ng/mL	
Morphine	Not Detected	20 ng/mL	also a metabolite of Codeine; may reflect poppy seed ingestion
6-acetylmorphine	Not Detected	20 ng/mL	heroin metabolite; morphine is expected
<b>OXYCODONE-LIKE, MASS SPEC</b>			
Oxycodone	Not Detected	40 ng/mL	
--Noroxycodone	Not Detected	100 ng/mL	oxycodone metabolite
Oxymorphone	Not Detected	40 ng/mL	eg, Opana; also a metabolite of oxycodone
--Noroxymorphone	Not Detected	100 ng/mL	oxymorphone metabolite; naloxone metabolite (i.e., nornaloxone)
Hydrocodone	Not Detected	40 ng/mL	also a minor metabolite of Codeine; possible impurity of oxycodone
--Norhydrocodone	Not Detected	100 ng/mL	hydrocodone metabolite
Hydromorphone	Not Detected	40 ng/mL	eg, Dilaudid; also a metabolite of hydrocodone, and a minor metabolite of morphine
<b>OPIOIDS, MASS SPEC</b>			
Buprenorphine	Not Detected	5 ng/mL	eg Suboxone, Subutex. Please note: detection of naloxone is not included
--Norbuprenorphine	Not Detected	20 ng/mL	buprenorphine metabolite
Fentanyl	<b>Present</b>	2 ng/mL	
--Norfentanyl	<b>Present</b>	2 ng/mL	fentanyl metabolite



Patient:  
ARUP Accession: 19-235-131690

# Pain Management Drug Screen with Interpretation by High-Resolution Time-of-Flight or Tandem Mass Spectrometry and Enzyme Immunoassay, Urine

Patient: \_\_\_\_\_ | Date of Birth: \_\_\_\_\_ | Gender: \_\_\_\_\_ | Physician: \_\_\_\_\_  
 Patient Identifiers: \_\_\_\_\_ | Visit Number (FIN): \_\_\_\_\_

Drug Analyte	Result	Cutoff	Notes
Meperidine metabolite	Not Detected	50 ng/mL	normeperidine
Tapentadol	Not Detected	100 ng/mL	
--Tapentadol-o-sulfate	Not Detected	200 ng/mL	tapentadol metabolite
<b>AMPHETAMINE-LIKE, MASS SPEC</b>			
Amphetamine	Not Detected	100 ng/mL	eg, Vyvanse; also a metabolite of methamphetamine
Methamphetamine	Not Detected	400 ng/mL	d- and l- isomers are not distinguished by this test; may reflect Vicks inhaler, Desoxyn, Selegiline, or illicit source
MDMA - Ecstasy	Not Detected	200 ng/mL	
MDA	Not Detected	200 ng/mL	also a metabolite of MDMA and MDEA
MDEA - Eve	Not Detected	200 ng/mL	
Phentermine	Not Detected	100 ng/mL	
Methylphenidate	Not Detected	100 ng/mL	eg, Ritalin, Dexmethylphenidate, Focalin, Concerta
<b>BENZODIAZEPINE-LIKE, MASS SPEC</b>			
Alprazolam	Not Detected	40 ng/mL	eg, Xanax
--Alpha-hydroxyalprazolam	Not Detected	20 ng/mL	alprazolam metabolite
Clonazepam	Not Detected	20 ng/mL	eg, Klonopin
--7-aminoclonazepam	Not Detected	40 ng/mL	clonazepam metabolite
Diazepam	Not Detected	50 ng/mL	eg, Valium
Nordiazepam	Not Detected	50 ng/mL	metabolite of chlordiazepoxide (Librium), clorazepate (Tranxene), diazepam, halazepam (Alapryl), prazepam (Centrax) and others
Oxazepam	Not Detected	50 ng/mL	eg, Serax; also metabolite of nordiazepam and temazepam
Temazepam	Not Detected	50 ng/mL	eg, Restoril; also a metabolite of diazepam
Lorazepam	Not Detected	60 ng/mL	eg, Ativan
Midazolam	Not Detected	20 ng/mL	eg, Versed
Zolpidem	Not Detected	20 ng/mL	eg, Ambien
Reference interval			
Creatinine value (mg/dL)	<b>27.1</b>	20.0 - 400.0 mg/dL	



Patient:  
ARUP Accession: 19-235-131690

# Pain Management Drug Screen with Interpretation by High-Resolution Time-of-Flight or Tandem Mass Spectrometry and Enzyme Immunoassay, Urine

Patient: | Date of Birth: | Gender: | Physician:  
Patient Identifiers: | Visit Number (FIN):

---

## Additional Information

### METHODOLOGIES USED

Qualitative Enzyme Immunoassay  
Qualitative Liquid Chromatography-Time of Flight-Mass Spectrometry or Tandem Mass Spectrometry  
Quantitative Spectrophotometry

### ABBREVIATIONS

MASS SPEC - Mass Spectrometry  
MDA - 3,4-methylenedioxyamphetamine  
MDEA - 3,4-methylenedioxy-N-ethylamphetamine  
MDMA - 3,4-methylenedioxy-N-methylamphetamine



Patient:  
ARUP Accession: 19-235-131690